MAPT and Alzheimer disease: A previous study that used the same STZ-ICV sporadic AD rat model demonstrated that STZ-ICV administration caused a decrease in PI3K-Akt signaling activity, GLUT expression, tau O-GlcNAcylation, hyperactivity of GSK-3β, and subsequent tau hyperphosphorylation [10].